-
Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai, Hangzhou (China), and San Jose, Seattle (United States), is set to fully acquire Fibernova Holding Corporation for a total consideration of USD 2.7 million. The acquisition includes a USD 1.7 million equity exchange…
-
Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced receiving market approval from the National Medical Products Administration (NMPA) for its in-house developed MemoSorb biodegradable patent foramen ovale occluder. This innovative device is now approved for use in patients aged 18 to 60 with…
-
EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies
•
Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the formation of a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal (GI) system and liver. The collaboration aims to leverage the combined expertise of both companies…
-
GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline
•
China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB 400 million (USD 54.8 million). The round was led by CICC, with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership, and existing investors Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China.…
-
Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening
•
Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection, has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series B+ financing round. The round was led by Fortune Capital, with additional investments from Tao Capital, Hotgen Biotech, and the company’s…
-
Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), has announced a market approval filing for its pipeline candidate A140, a biosimilar version of Merck KGaA/Bristol-Myers Squibb’s (NYSE: MRK/BMS, NYSE: BMY) cetuximab, known under the trade name Erbitux. The…
-
Biotyx Medical Secures Over RMB 200 Million in Series B Financing for Iron-Based Stents
•
China-based Biotyx Medical (Shenzhen) Co.,Ltd, known as the world’s only developer of iron-based absorbable stents, has reportedly raised over RMB 200 million (USD 27.4 million) in a Series B financing round. The investors in this round include Gongqingcheng Huayi Private Equity Fund Management, Guangfa Qianhe Investment, IDG Capital, and Shanghai…
-
United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China
•
Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1 drug candidate UBT251 has been tacitly approved in China for a clinical study focusing on non-alcoholic fatty liver disease (NAFLD). UBT251: A Triple Agonist for Metabolic ImprovementsUBT251 is a long-acting GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent…
